Hapvida Participacoes e Investimentos (HAPV3) Q2 2024 earnings summary

Executive summary

• Achieved strong operational and financial performance in Q2 2024, with significant improvements in margins and cash generation, driven by verticalization, integration, and disciplined portfolio management.

• Net revenue grew 4.5% year-over-year to R$7,150MM in Q2 2024, driven by higher average ticket prices despite a decline in beneficiaries.

• Adjusted EBITDA surged 58% year-over-year to R$958MM, reflecting effective price adjustments and cost control.

• Integration of operations in São Paulo, Rio de Janeiro, and Minas Gerais led to quality improvements and reduced complaints.

• Launched new products targeting retail and small businesses, and expanded own network through new hospital projects and built-to-suit (BTS) financing.

Financial highlights

• Consolidated net revenue reached R$7,150MM in Q2 2024, up 4.5% year-over-year, and R$14,142MM in H1 2024, up 4.2%.

• Adjusted EBITDA was R$958MM (13.4% margin) in Q2 2024, up from R$606MM (8.9%) in Q2 2023.

• Adjusted net income rose 121% year-over-year in Q2 2024 and over 290% in H1 2024.

• Free cash flow was R$307.4MM in Q2 2024, with 56.3% EBITDA-to-cash conversion.

• Net debt reduced to R$4,348MM, with leverage at 1.03x EBITDA, down from 1.13x sequentially.

Outlook and guidance

• Optimistic about organic growth as gross sales exceeded cancellations for the first time since early 2023.

• Expect continued margin improvement as integration and verticalization strategies mature, with full benefits anticipated after October system rollout.

• Ongoing focus on price recomposition, portfolio optimization, and verticalization to sustain profitability.

• CapEx for 2024 projected at around R$700MM, with freed-up capital from BTS transactions enabling acceleration of network expansion.

• Continued integration and system simplification expected to drive further efficiency and quality gains.